Affiliation:
1. Clinic of Urology University Clinical Center of Serbia Belgrade Serbia
2. Faculty of Medicine University of Belgrade Belgrade Serbia
3. Center Of Nuclear Medicine University Clinical Center of Serbia Belgrade Serbia
4. Institute of Epidemiology, Faculty of Medicine University of Belgrade Belgrade Serbia
Abstract
AbstractObjectiveWe aimed to assess the prognostic value of De Ritis ratio on oncological outcomes in patients suffering from urothelial bladder cancer and undergoing radical cystectomy (RC).Patients and MethodsAnalytical cohort comprised a single‐center series of 367 patients treated between January 2015 and December 2018. Patients were classified into two groups based on De Ritis ratio (<1.3 [normal] vs. ≥1.3 [high]). Along with the Kaplan‐Meier survival probability, cox proportional hazard regression models were used.ResultsA total of 299 patients were included, 60.5% of them having a De Ritis ratio of <1.3% and 39.5% with a De Ritis ratio of ≥1.3. Preoperative increased De Ritis ratio was associated with age (p = 0.001), gender (p = 0.044), cancer‐related death (p = 0.001), overall death (p = 0.001), and tumor stage (p = 0.001). Multivariate analysis implied that preoperative De Ritis ratio was a significant independent prognosticator of overall survival (HR 0.461; 95% CI 0.335–0.633; p < 0.001) and CSS (HR 0.454; 95% CI 0.330–0.623; p < 0.001). Only tumor stage (HR 1.953; 95% CI 1. 106–3.448; p = 0.021) was independently associated with recurrence‐free survival (RFS). De Ritis ratio was not independently associated with RFS in multivariate analyses. During the follow up, a total of 198 (66.2%) patients died, including 173 (57.9%) from BC, 5‐year CSS was 45.8%.ConclusionsDe Ritis ratio is an independent prognostic factor of cancer specific and overall survival in patients treated with RC for urothelial BC. RC patients may benefit from the use of the De Ritis ratio as a valid predictive biomarker.
Subject
Oncology,General Medicine,Surgery